HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Laboratories Inc.

Division of Allergan PLC
www.frx.com

Latest From Forest Laboratories Inc.

Daraprim Drug Pricing Suit Against Shkreli And Vyera May Signal Future FTC Actions

In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.

Legal Issues Pricing Strategies

Teva And Cipla Will Have ANDAs Withdrawn

Watson (now Teva) and InvaGen (now Cipla) failed to submit new bioequivalence data following enforcement action against Cetero Research.

Regulation Approvals

After Ignoring Letters From US FDA, Teva And Cipla Will Have ANDAs Withdrawn

Watson (now Teva) and InvaGen (now Cipla) failed to submit new bioequivalence data following enforcement action against Cetero Research.

FDA Generic Drugs

Namenda Product Hopping Settlement Surpasses Most Recent DOJ Agreements

Direct purchasers' $750m settlement with Allergan is at least the second involving product hopping claims; only one DOJ settlement surpassed this amount in the past year.

Legal Issues Intellectual Property
See All

Company Information

UsernamePublicRestriction

Register